8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Nov 6, 2025·SEC
CytomX Therapeutics, Inc.(CTMX)Earnings, Financials & Key Ratios
CTMX•NASDAQ
$4.13
$703M mkt cap·Price updated May 6, 2026
AboutCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Show more
- Revenue$76M-44.8%
- EBITDA-$18M-168.0%
- Net Income-$17M-154.5%
- EPS (Diluted)-0.15-139.5%
- Gross Margin100%
- EBITDA Margin-23.87%-223.2%
- Operating Margin-25.67%-241.9%
- Net Margin-22.79%-198.8%
- ROE-35.25%
- ROIC-47.75%
- Debt/Equity0.04
CTMX Key Insights
CytomX Therapeutics, Inc. (CTMX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 62.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CTMX Price & Volume
CytomX Therapeutics, Inc. (CTMX) stock price & volume — 10-year historical chart
Loading chart...
CTMX Growth Metrics
CytomX Therapeutics, Inc. (CTMX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years25.74%
5 Years2.18%
3 Years12.75%
TTM-44.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-154.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-97.8%
Return on Capital
10 Years-21.23%
5 Years-14.25%
3 Years8.52%
Last Year-28.01%
CTMX Recent Earnings
CytomX Therapeutics, Inc. (CTMX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Mar 16, 2026EPS
$0.22
Est $0.08
-175.0%
Revenue
$661,000
Est $7M
-91.0%
Q4 2025
Nov 6, 2025EPS
$0.09
Est $0.05
-82.5%
Revenue
$6M
Est $7M
-18.6%
Q3 2025
Aug 7, 2025EPS
$0.00
Est $0.06
+98.1%
Revenue
$19M
Est $18M
+2.1%
Q2 2025
May 12, 2025EPS
$0.27
Est $0.12
+116.3%
Revenue
$51M
Est $35M
+43.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 16, 2026 | $0.22vs $0.08-175.0% | $661,000vs $7M-91.0% |
| Q4 2025 | Nov 6, 2025 | $0.09vs $0.05-82.5% | $6Mvs $7M-18.6% |
| Q3 2025 | Aug 7, 2025 | $0.00vs $0.06+98.1% | $19Mvs $18M+2.1% |
| Q2 2025 | May 12, 2025 | $0.27vs $0.12+116.3% | $51Mvs $35M+43.7% |
Based on last 12 quarters of dataView full earnings history →
CTMX Peer Comparison
CytomX Therapeutics, Inc. (CTMX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PBYI | 379.14M | 7.45 | 12.21 | -0.91% | 13.6% | 27.78% | 0.22 | |
 TPST | 56.36M | 2.02 | -1.35 | -5.68% | 0.80 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 ALXO | 111.98M | 2.09 | -0.81 | -241.09% | 0.15 |
Compare CTMX vs Peers
CytomX Therapeutics, Inc. (CTMX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTMX Income Statement
CytomX Therapeutics, Inc. (CTMX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 71.62M | 59.5M | 57.49M | 68.43M | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Revenue Growth % | 376.12% | -16.92% | -3.38% | 19.03% | -45.47% | 42.48% | 90.38% | 36.45% | -44.82% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 71.62M▲ 0% | 59.5M▼ 16.9% | 57.49M▼ 3.4% | 68.43M▲ 19.0% | 37.31M▼ 45.5% | 53.16M▲ 42.5% | 101.21M▲ 90.4% | 138.1M▲ 36.4% | 76.2M▼ 44.8% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | 376.12% | -16.92% | -3.38% | 19.03% | -45.47% | 42.48% | 90.38% | 36.45% | -44.82% |
| Operating Expenses | 117.88M | 137.38M | 168.38M | 148.97M | 153.35M | 154.5M | 107.7M | 113.11M | 95.77M |
| OpEx % of Revenue | 164.59% | 230.88% | 292.9% | 217.7% | 411% | 290.61% | 106.41% | 81.9% | 125.67% |
| Selling, General & Admin | 25.61M | 33.51M | 36.77M | 36.03M | 39.16M | 42.85M | 30.02M | 29.73M | 29.97M |
| SG&A % of Revenue | 35.75% | 56.32% | 63.95% | 52.66% | 104.95% | 80.6% | 29.66% | 21.52% | 39.33% |
| Research & Development | 92.28M | 103.87M | 131.62M | 112.94M | 114.19M | 111.65M | 77.68M | 83.38M | 65.8M |
| R&D % of Revenue | 128.84% | 174.56% | 228.95% | 165.05% | 306.05% | 210.01% | 76.75% | 60.38% | 86.35% |
| Other Operating Expenses | -27K | -68K | -135K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -46.26M▲ 0% | -77.87M▼ 68.3% | -110.89M▼ 42.4% | -80.54M▲ 27.4% | -116.04M▼ 44.1% | -101.33M▲ 12.7% | -6.48M▲ 93.6% | 25M▲ 485.5% | -19.56M▼ 178.3% |
| Operating Margin % | -64.59% | -130.88% | -192.9% | -117.7% | -311% | -190.61% | -6.41% | 18.1% | -25.67% |
| Operating Income Growth % | 22.37% | -68.34% | -42.4% | 27.37% | -44.08% | 12.67% | 93.6% | 485.49% | -178.27% |
| EBITDA | -44.61M | -75.99M | -108.29M | -77.97M | -113.34M | -98.89M | -4.31M | 26.76M | -18.19M |
| EBITDA Margin % | -62.29% | -127.71% | -188.37% | -113.94% | -303.75% | -186.02% | -4.26% | 19.38% | -23.87% |
| EBITDA Growth % | 22.88% | -70.33% | -42.51% | 28% | -45.36% | 12.74% | 95.64% | 721.1% | -167.96% |
| D&A (Non-Cash Add-back) | 1.65M | 1.88M | 2.6M | 2.57M | 2.71M | 2.44M | 2.17M | 1.77M | 1.38M |
| EBIT | -43.61M | -77.87M | -102.67M | -80.54M | -116.04M | -101.33M | -6.48M | 25M | -19.56M |
| Net Interest Income | 2.67M | 7.64M | 8.37M | 1.84M | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Income | 2.67M | 7.64M | 8.37M | 1.84M | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.65M | 7.57M | 8.23M | 29.63M | 172K | 2.02M | 9.81M | 7.1M | 2.43M |
| Pretax Income | -43.61M▲ 0% | -70.3M▼ 61.2% | -102.67M▼ 46.0% | -50.91M▲ 50.4% | -115.87M▼ 127.6% | -99.32M▲ 14.3% | 3.32M▲ 103.3% | 32.09M▲ 865.8% | -17.13M▼ 153.4% |
| Pretax Margin % | -60.89% | -118.15% | -178.58% | -74.4% | -310.54% | -186.82% | 3.28% | 23.24% | -22.48% |
| Income Tax | -513K | 14.3M | -427K | 13.91M | 0 | 0 | 3.89M | 224K | 238K |
| Effective Tax Rate % | 1.18% | -20.35% | 0.42% | -27.33% | 0% | 0% | 117.12% | 0.7% | -1.39% |
| Net Income | -43.1M▲ 0% | -84.6M▼ 96.3% | -102.24M▼ 20.8% | -64.82M▲ 36.6% | -115.87M▼ 78.8% | -99.32M▲ 14.3% | -569K▲ 99.4% | 31.87M▲ 5700.9% | -17.37M▼ 154.5% |
| Net Margin % | -60.17% | -142.19% | -177.84% | -94.73% | -310.54% | -186.82% | -0.56% | 23.08% | -22.79% |
| Net Income Growth % | 26.83% | -96.3% | -20.84% | 36.6% | -78.76% | 14.29% | 99.43% | 5700.88% | -154.5% |
| Net Income (Continuing) | -43.1M | -84.6M | -102.24M | -64.82M | -115.87M | -99.32M | -569K | 31.87M | -17.37M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.16▲ 0% | -2.03▼ 75.0% | -2.26▼ 11.3% | -0.71▲ 68.6% | -1.26▼ 77.5% | -1.48▼ 17.5% | -0.01▲ 99.5% | 0.38▲ 5035.1% | -0.15▼ 139.5% |
| EPS Growth % | 28.83% | -75% | -11.33% | 68.58% | -77.46% | -17.46% | 99.48% | - | -139.47% |
| EPS (Basic) | -1.16 | -2.03 | -2.26 | -0.71 | -1.26 | -1.48 | -0.01 | 0.38 | -0.15 |
| Diluted Shares Outstanding | 37.17M | 41.66M | 45.34M | 46.15M | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
| Basic Shares Outstanding | 37.17M | 41.66M | 45.34M | 46.15M | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CTMX Balance Sheet
CytomX Therapeutics, Inc. (CTMX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 388.6M | 445.48M | 303.33M | 324.01M | 310.3M | 237.1M | 182.94M | 107.31M | 143.92M |
| Cash & Short-Term Investments | 374.11M | 436.13M | 296.14M | 316.12M | 305.23M | 193.65M | 174.51M | 100.62M | 137.05M |
| Cash Only | 177.55M | 247.58M | 188.43M | 191.86M | 205.53M | 193.65M | 17.17M | 38.05M | 12.67M |
| Short-Term Investments | 196.56M | 188.55M | 107.72M | 124.26M | 99.7M | 0 | 157.34M | 62.57M | 124.39M |
| Accounts Receivable | 10.14M | 97K | 13K | 798K | 790K | 35.99M | 3.43M | 3.1M | 2.01M |
| Days Sales Outstanding | 51.67 | 0.59 | 0.08 | 4.26 | 7.73 | 247.07 | 12.38 | 8.2 | 9.64 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 4.35M | 9.25M | 0 | 0 | 0 | 7.47M | 5M | 3.58M | 4.86M |
| Total Non-Current Assets | 9.04M | 11.63M | 37.95M | 34.65M | 29.11M | 23.79M | 18.86M | 13.23M | 7.64M |
| Property, Plant & Equipment | 4.22M | 6.93M | 32.75M | 29.45M | 25.32M | 21.02M | 16.18M | 10.6M | 4.7M |
| Fixed Asset Turnover | 16.98x | 8.58x | 1.76x | 2.32x | 1.47x | 2.53x | 6.26x | 13.02x | 16.21x |
| Goodwill | 949K | 949K | 949K | 949K | 949K | 949K | 949K | 949K | 949K |
| Intangible Assets | 1.6M | 1.46M | 1.31M | 1.17M | 1.02M | 875K | 729K | 583K | 438K |
| Long-Term Investments | 917K | 917K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 957K | 238K | 2.93M | 3.09M | 1.82M | 944K | 1M | 1.09M | 1.56M |
| Total Assets | 397.64M▲ 0% | 457.11M▲ 15.0% | 341.28M▼ 25.3% | 358.66M▲ 5.1% | 339.41M▼ 5.4% | 260.89M▼ 23.1% | 201.79M▼ 22.7% | 120.53M▼ 40.3% | 151.57M▲ 25.7% |
| Asset Turnover | 0.18x | 0.13x | 0.17x | 0.19x | 0.11x | 0.20x | 0.50x | 1.15x | 0.50x |
| Asset Growth % | 99.69% | 14.95% | -25.34% | 5.09% | -5.37% | -23.13% | -22.65% | -40.27% | 25.75% |
| Total Current Liabilities | 61.15M | 97.91M | 85.59M | 68.11M | 77.87M | 152.61M | 155.91M | 85.77M | 46.62M |
| Accounts Payable | 4.21M | 5.13M | 4.16M | 3M | 2.82M | 2.81M | 1.46M | 1.09M | 1.3M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.24M |
| Deferred Revenue (Current) | 40.56M | 52.71M | 51.38M | 42.06M | 40.82M | 121.27M | 132.27M | 67.2M | 26.88M |
| Other Current Liabilities | 11.86M | 20.14M | 0 | 0 | 0 | 0 | 9.44M | 0 | 5.99M |
| Current Ratio | 6.36x | 4.55x | 3.54x | 4.76x | 3.98x | 1.55x | 1.17x | 1.25x | 3.09x |
| Quick Ratio | 6.36x | 4.55x | 3.54x | 4.76x | 3.98x | 1.55x | 1.17x | 1.25x | 3.09x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 266.6M | 228.32M | 204.58M | 298.33M | 262M | 194.03M | 93.33M | 35.22M | 5.94M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 24.87M | 21.68M | 18.06M | 13.97M | 9.38M | 4.24M | 0 |
| Deferred Tax Liabilities | 398K | 1.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.9M | 3.05M | 850K | 0 | 0 | 0 | 3.89M | 4.12M | 5.94M |
| Total Liabilities | 327.75M | 326.23M | 290.17M | 366.44M | 339.87M | 346.64M | 249.24M | 120.99M | 52.56M |
| Total Debt | 0 | 0 | 27.68M | 24.87M | 21.67M | 18.06M | 13.97M | 9.38M | 4.24M |
| Net Debt | -177.55M | -247.58M | -160.74M | -166.99M | -183.86M | -175.59M | -3.2M | -28.67M | -8.43M |
| Debt / Equity | - | - | 0.54x | - | - | - | - | - | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.35x | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -1.07x | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 69.9M▲ 0% | 130.88M▲ 87.3% | 51.11M▼ 60.9% | -7.77M▼ 115.2% | -459K▲ 94.1% | -85.75M▼ 18582.1% | -47.45M▲ 44.7% | -456K▲ 99.0% | 99.01M▲ 21812.3% |
| Equity Growth % | -10.94% | 87.25% | -60.95% | -115.21% | 94.1% | -18582.14% | 44.67% | 99.04% | 21812.28% |
| Book Value per Share | 1.88 | 3.14 | 1.13 | -0.17 | -0.01 | -1.30 | -0.64 | -0.01 | 0.72 |
| Total Shareholders' Equity | 69.9M | 130.88M | 51.11M | -7.77M | -459K | -85.75M | -47.45M | -456K | 99.01M |
| Common Stock | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 2K |
| Retained Earnings | -219.47M | -314.98M | -417.23M | -507.69M | -623.56M | -722.88M | -723.45M | -691.58M | -711.95M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -94K | -93K | 57K | -47K | -242K | 10K | 95K | 27K | 111K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTMX Cash Flow Statement
CytomX Therapeutics, Inc. (CTMX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 170.37M | -75.52M | -140.48M | 5.26M | -119.03M | -110.79M | -56.03M | -86.23M | -75.59M |
| Operating CF Margin % | 237.87% | -126.92% | -244.36% | 7.69% | -319.02% | -208.39% | -55.36% | -62.44% | -99.19% |
| Operating CF Growth % | 8484.5% | -144.33% | -86.01% | 103.74% | -2363.38% | 6.93% | 49.42% | -53.89% | 12.34% |
| Net Income | -43.1M | -84.6M | -132.82M | -32.88M | -83.61M | -99.32M | -569K | 31.87M | -20.37M |
| Depreciation & Amortization | 1.65M | 1.88M | 2.6M | 2.57M | 2.71M | 5.86M | 2.17M | 1.77M | 146K |
| Stock-Based Compensation | 11.29M | 16.88M | 19.1M | 14.79M | 13.17M | 0 | 8.56M | 7.67M | 6.3M |
| Deferred Taxes | -513K | 0 | 0 | -236K | 272K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 11.09M | -1.7M | 2.05M | 2.89M | 3.13M | 13.33M | -3.69M | -1.12M | 6.91M |
| Working Capital Changes | 189.97M | -7.98M | -31.41M | 18.13M | -54.7M | -30.65M | -62.51M | -126.42M | -68.58M |
| Change in Receivables | -7.83M | 10.04M | 84K | -785K | 8K | -35.2M | 32.55M | 329K | 1.09M |
| Change in Inventory | 10.32M | 19.91M | 0 | -11.12M | 11.64M | 0 | 0 | 0 | 0 |
| Change in Payables | -2.44M | 261K | -374K | -857K | -139K | 68K | -1.43M | -297K | 221K |
| Cash from Investing | -121.27M | 5.93M | 79.7M | -18.72M | 22.49M | 98.26M | -150.67M | 99.7M | -59.74M |
| Capital Expenditures | -1.56M | -3.79M | -3.5M | -2.31M | -1.61M | -1.74M | -840K | -310K | -220K |
| CapEx % of Revenue | 2.18% | 6.37% | 6.08% | 3.37% | 4.31% | 3.27% | 0.83% | 0.22% | 0.29% |
| Acquisitions | 121.27M | -5.93M | 0 | 16.41M | -24.1M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -121.27M | 5.93M | 0 | -16.41M | 24.1M | 0 | 0 | 0 | 0 |
| Cash from Financing | 23.8M | 139.62M | 1.63M | 16.89M | 110.21M | 648K | 30.23M | 7.52M | 110.45M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 648K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 3.84M | 5.03M | 1.63M | 5.61M | 2.5M | 0 | 0 | 613K | 3M |
| Net Change in Cash | 72.9M▲ 0% | 70.03M▼ 3.9% | -59.15M▼ 184.5% | 3.43M▲ 105.8% | 13.67M▲ 298.1% | -11.88M▼ 186.9% | -176.48M▼ 1385.5% | 20.99M▲ 111.9% | -24.89M▼ 218.6% |
| Free Cash Flow | 168.81M▲ 0% | -79.31M▼ 147.0% | -143.98M▼ 81.5% | 2.95M▲ 102.0% | -120.64M▼ 4189.5% | -112.53M▲ 6.7% | -56.88M▲ 49.5% | -86.54M▼ 52.2% | -75.81M▲ 12.4% |
| FCF Margin % | 235.7% | -133.29% | -250.44% | 4.31% | -323.33% | -211.67% | -56.19% | -62.66% | -99.48% |
| FCF Growth % | 4111.74% | -146.98% | -81.54% | 102.05% | -4189.49% | 6.72% | 49.46% | -52.16% | 12.4% |
| FCF per Share | 4.54 | -1.90 | -3.18 | 0.06 | -1.88 | -1.71 | -0.77 | -1.02 | -0.55 |
| FCF Conversion (FCF/Net Income) | -3.95x | 0.89x | 1.37x | -0.08x | 1.03x | 1.12x | 98.48x | -2.71x | 4.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 13.06M | 0 | 0 | 0 | 0 | 0 | 0 |
CTMX Key Ratios
CytomX Therapeutics, Inc. (CTMX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -57.59% | -58.09% | -84.28% | -112.35% | -299.13% | - | - | - | - | -35.25% |
| Return on Invested Capital (ROIC) | -223% | - | - | - | - | - | - | - | - | -47.75% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -391.54% | -60.17% | -142.19% | -177.84% | -94.73% | -310.54% | -186.82% | -0.56% | 23.08% | -22.79% |
| Debt / Equity | - | - | - | 0.54x | - | - | - | - | - | 0.04x |
| Interest Coverage | -35.28x | - | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.03x | -3.95x | 0.89x | 1.37x | -0.08x | 1.03x | 1.12x | 98.48x | -2.71x | 4.35x |
| Revenue Growth | 95.06% | 376.12% | -16.92% | -3.38% | 19.03% | -45.47% | 42.48% | 90.38% | 36.45% | -44.82% |
CTMX SEC Filings & Documents
CytomX Therapeutics, Inc. (CTMX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CTMX Frequently Asked Questions
CytomX Therapeutics, Inc. (CTMX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CytomX Therapeutics, Inc. (CTMX) reported $76.2M in revenue for fiscal year 2025. This represents a 8481% increase from $0.9M in 2013.
CytomX Therapeutics, Inc. (CTMX) saw revenue decline by 44.8% over the past year.
CytomX Therapeutics, Inc. (CTMX) reported a net loss of $17.4M for fiscal year 2025.
Dividend & Returns
Yes, CytomX Therapeutics, Inc. (CTMX) pays a dividend with a yield of 0.53%. This makes it attractive for income-focused investors.
CytomX Therapeutics, Inc. (CTMX) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.
CytomX Therapeutics, Inc. (CTMX) had negative free cash flow of $75.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More CTMX
CytomX Therapeutics, Inc. (CTMX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates